Clinical trials: Advanced Carcinoma
Advanced Non-small Cell Lung Cancer, EGFR Mutation
A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called EGFR and HER2 mutations.
- Conditions
- Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
- Trial name
- NCT06348888
- Testing
- BAY2927088, Itraconazole, Carbamazepine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Nasopharyngeal Carcinoma (NPC), Radiation-induced Oral Mucositis
Pre-Radiotherapy n-6/n-3 Fatty Acid Ratio Predicts Severe Oral Mucositis in Nasopharyngeal Carcinoma
The goal of this clinical trial is to learn if the balance of omega-6 and omega-3 fats in red blood cells can predict severe mouth sores caused by radiation therapy in people with locally advanced nasopharyngeal carcinoma (a type…
- Conditions
- Nasopharyngeal Carcinoma (NPC), Radiation-induced Oral Mucositis, Head and Neck Neoplasms
- Trial name
- NCT07920250
- Testing
- Toripalimab (240mg day1, Q3W*3cycle), Cisplatin (80 mg/m2), Nab-paclitaxel
- Where
- China
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
This is a single-arm，open-label study to evaluate the efficacy and safety of tislelizumab plus chemotherapy for conversion therapy of patients with locally nonresectable ESCC.
- Trial name
- NCT05469061
- Testing
- Tislelizumab, 5-FU, cis Platinum
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non Small Cell Lung Cancer
Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC
This study aims to investigate the efficacy and safety of fecal microbiota transplantation (FMT) as a treatment for non-small cell lung cancer (NSCLC) patients whose disease has progressed after immune checkpoint inhibitor (ICI)…
- Trial name
- FMT-LUNG (NCT07432984)
- Testing
- Tislelizumab, Fecal Microbiota Transplant(FMT)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Se-Hoon Lee
Colorectal Carcinoma, Advanced Adenomas (AA)
Development and Validation of a Blood Test for Early Diagnosis of Colorectal Cancer
This is a prospective, multicenter, case-control study. The aim is to develop an optimized algorithm by combining the levels of molecular markers in plasma together with risk factors for developing colorectal cancer and clinical…
- Trial name
- ColoDix (NCT06889883)
- Where
- 9 sites in Spain
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- ADVANCED MARKER DISCOVERY S.L.
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
NSCLC (advanced Non-small Cell Lung Cancer)
Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function
This study will be conducted in subjects with moderate Hepatic Impairment, mild hepatic Impairment and normal hepatic function. The study will be conducted in two stages.
- Trial name
- NCT06823258
- Testing
- HS-10365
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Nasopharyngeal Carcinoma
Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With IMRT Of Locally Advanced NPC Clinical Study
Comparing induction chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy (chrono-chemotherapy group) with induction chemotherapy followed by cisplatin…
- Trial name
- NCT02187315
- Testing
- Chrono-chemotherapy pump:Melodie, Routine intravenous drip, induction chemotherapy
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Feng Jing
Hepatocellular Carcinoma
RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)
Hepatocellular carcinoma (HCC) is a common malignancy, and its incidence is expected to increase in many countries in coming decades. Approximately 70-80% of newly diagnosed HCC patients already have advanced disease.
- Trial name
- NCT04193696
- Testing
- Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Non-small Cell Lung Cancer
Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer
This study was designed to explore the efficacy and safety of Crizotinib as a first-line treatment for advanced NSCLC with ROS1 rearrangement positive mutation in the real world, explore the new drug resistance mechanism of ROS1…
- Trial name
- NCT03646994
- Testing
- Crizotinib
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hunan Province Tumor Hospital
Cancer
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
This is a Phase Ib, open-label, multiple-center, multiple-dose study designed to evaluate the pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies (including hepatocellular carcinoma and…
- Trial name
- NCT01546519
- Testing
- Vismodegib
- Where
- 5 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Squamous Cell Carcinoma of Head and Neck
Concurent Chemoradiotherapy in Head and Neck Cancers
To compare the efficacy and toxicities of the combination between weekly docitaxel and cisplatin (every3 week) concurrent with radiation versus the standard concurrent chemoradiotherapy with high dose cisplatin (100mg\m2) for…
- Trial name
- NCT04780750
- Testing
- Docetaxel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Liver Cancer
Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00467194
- Testing
- Rapamycin, Bevacizumab
- Where
- 2 sites in Singapore
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Cancer Centre, Singapore
Carcinoma, Non-Small-Cell Lung
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Demonstrate feasibility of detection of EML4-ALK fusion transcripts and T790M EGFR mutation from exosomes in the circulation of Non-Small Cell Lung Cancer (NSCLS) patients.
- Trial name
- NCT03236675
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
Recurrence, Metastasis
Prognostic Value of CTC in HNSCC Patients
We hypothesized that the number of circulating tumor cells (CTCs) and molecular markers on CTCs could be a prognostic factor or predictive factor to patients with head neck cancer.
- Conditions
- Recurrence, Metastasis, Death
- Trial name
- CTCHNSCC01 (NCT01884129)
- Where
- Taiwan
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Advanced Renal Cell Carcinoma
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy as…
- Trial name
- NCT05522231
- Testing
- fruquintinib+sintilimab, axitinib / everolimus, fruquintinib
- Where
- 48 sites in China
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Carcinoma, Hepatocellular
A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma
Hepatocarcinoma (HCC) is the first cause of deaths due to cancer worldwide. More than one million two hundred thousand new patients are diagnosed each year.
- Trial name
- THBC002 (NCT00440934)
- Testing
- Amplitude-modulated electromagnetic fields
- Where
- Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pasche, Boris, M.D.
HCC - Hepatocellular Carcinoma
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
This research plan involves a treatment approach for advanced hepatocellular carcinoma (HCC) in the context of metabolic-associated steatotic liver disease (MASLD).
- Trial name
- ABATE-MASLD (NCT07285850)
- Testing
- Sequential treatment of bevacizumab combined with atezolizumab (sequential group), Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Non-Small Cell Lung Cancer
Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients
Several reports have examined Programmed Death 1 (PD-1) expression on tumor-infiltrating T-cells, and its correlation with prognosis has been discussed.
- Trial name
- NCT02758314
- Testing
- Evaluation of PD-1/PDL-1 expression.
- Where
- Mexico
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Cancerologia de Mexico